Otsuka Pharmaceutical Europe was founded in 1998. Otsuka Pharmaceutical Europe markets drugs and health care products manufactured by its Japan-based parent, Otsuka Pharmaceutical. The company also conducts research and development of pharmaceuticals, focusing on the fields of gastroenterology, neurology, ophthalmology, and the cardiovascular system. Marketed drugs include schizophrenia treatment Abilify (through a partnership with Bristol-Myers Squibb), Adacolumn for inflammatory bowel disease, Mikelan for ocular glaucoma and hypertension, Pletal for peripheral vascular disease, and UBiT for gastrointestinal infection diagnosis.

Rules-Based Medicine, Inc. company was founded in 1998 and is headquartered in Austin, Texas. Rules-Based Medicine, Inc., a life sciences company, focuses on the development and commercialization of molecular diagnostic tests based on novel biomarker patterns primarily for the psychiatric market. It develops molecular diagnostic tests using its proprietary multi-analyte profiling, or MAP, technology that helps to screen large sets of well-characterized clinical samples from both diseased and non-diseased populations against a menu of biomarker immunoassays. The company’s pharmaceutical services consist of MAP testing services, custom MAP services, multiplexed immunoassay kits, and TruCulture and other co-culture services. It markets its laboratory testing products and services primarily to drug development professionals at pharmaceutical and biotechnology companies.

Anacor Pharmaceuticals is a biopharmaceutical company developing novel small-molecule therapeutics derived from its boron chemistry platform to treat infectious and inflammatory diseases. Anacor's most advanced product candidate is AN2690, a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. Anacor also has a portfolio of other topical product candidates in development for the treatment of psoriasis, atopic dermatitis and skin and nail fungal infections. The company has entered into a worldwide license, development and commercialization agreement with Merck for the development and commercialization of AN2690 for all indications including the treatment of onychomycosis. In addition, Anacor has a research and development agreement with GSK for novel antiviral and antibacterial systemic therapeutics.

Johnson & Johnson company was founded in 1886 and is based in New Brunswick, New Jersey. Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. Johnson & Johnson has more than 250 operating companies. The Company operates in three segments. The Consumer segment includes a range of products used in the baby care, skin care, oral care, wound care and women’s healthcare fields, as well as nutritional and over-the-counter pharmaceutical products. The Pharmaceutical segment includes products in the therapeutic areas, such as anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. The Medical Devices and Diagnostics segment includes a range of products distributed to wholesalers, hospitals and retailers. In July 2009, Johnson & Johnson completed the acquisition of Cougar Biotechnology, Inc. with approximately 95.9% interest in Cougar Biotechnology's outstanding common stock.

Quest PharmaTech aims to shed some light on dermatology and cancer treatments. Working with Hypocrellin, a photosensitive compound isolated from pigments found in fungi on bamboo, the company has developed its SonoLight Technology. The compound is relatively harmless until activated by light or ultrasound, whereupon it begins to destroy tissue. The company's pipeline of drug candidates include treatments to facilitate laser hair removal, address acne, and improve prostate cancer therapies. The company has sold off several earlier products to focus on its current pipeline and continues to consider strategic alternatives to facilitate its growth.

CEO Alexander Kozak founded D-Pharm Ltd. in 1993. D-Pharm de-velops and de-livers biopharmaceuticals to treat a variety of diseases. The company focuses on discovery and development of lipid-based compounds used primarily against central nervous system disorders. Drugs currently approaching the market include treatments for epilepsy, bipolar disorder, and stroke. The company's pipeline also includes drugs intended to fight Alzheimer's disease, Parkinson's disease, psoriasis, bowel disease, and cancer. D-Pharm partners with other drug companies to bring its treatments to market.

Incyte hopes its success with inhibitors is uninhibited. The biotechnology company is focused on discovering and developing drugs that inhibit specific enzymes associated with cancer, diabetes, HIV, and inflammatory diseases. The company's lede program is its JAK kinase inhibitor program, which covers treatments for inflammatory diseases and cancers, including rheumatoid arthritis, myelofibrosis, psoriasis, multiple myeloma, and prostate cancer. Incyte has several other products in clinical trial stages, including a CCR5 antagonist designed to prevent the entry of HIV into target cells.

QuA Vodis aims to help biotechnology and pharmaceutical companies get where they are going. The company, whose name shouldn't be confused with the movie Quo Vadis, offers interim management, quality assurance system development and training, and regulatory assistance to firms engaged in human and veterinary medical research. Its main focus for consultations is to enable the organizations to maintain operations and quality with as little internal disruption as possible. QuA Vodis has experience working with products such as sterile injectibles, radiopharmaceuticals, and blood and tissue products.

Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe. The company's primary product includes Tyzeka/Sebivo for the treatment of hepatitis B virus. It also develops IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for the treatment of human immunodeficiency virus (HIV)/ acquired immune deficiency syndrome (AIDS). In addition, Idenix Pharmaceuticals, Inc. focuses on the development of drugs for the treatment of hepatitis C virus. It has a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize its NNRTI compounds, including IDX899 for the treatment of HIV/AIDS. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts. Idenix Pharmaceuticals, Inc. is a subsidiary of Novartis Pharma AG.

Bridgehead International wants to give its clients a head start. The consulting firm operates four divisions that provide a variety of services to a broad spectrum of life science companies and academic groups. Its transaction support division offers technical and commercial advice to firms developing new health care products. Healthcare education services creates medical education and communications programs for the pharmaceutical industry. The market access strategy segment helps companies evaluate competitive pricing and reimbursement models, while opportunity assessment helps firms understand the markets they are attempting to enter. The company operates across Europe, Asia, and North America.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.